1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in Europe Countries, November 2019

Healthcare Analysis & Statistics in Europe Countries, November 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

data types

1-12 of 12 reports

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • $ 6948
  • Industry report
  • March 2018

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact: Melanoma (EU5) 2018

Market Access Impact: Melanoma (EU5) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out?In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two ...

  • Industries : Health Services
  • Countries : United Kingdom, United States
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • Industry report
  • February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America, United Kingdom
Psoriasis: Update Bulletin [January 2018]

Psoriasis: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); ...

  • Industries : Pathology, Biotechnology
  • Countries : Europe, European Union
Cystic Fibrosis: Update Bulletin #3

Cystic Fibrosis: Update Bulletin #3

  • $ 1151
  • Industry report
  • December 2017

This edition presents world leading key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; expert opinions on Vertex Pharmaceuticals’ regulatory ...

  • Industries : Therapy
  • Countries : United States, Europe, World, European Union
Value Added Services in Cardiometabolic Diseases -- Payer views

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • Industry report
  • October 2017

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • Industries : Chronic Disease
  • Countries : United States, World, European Union
Colorectal Cancer [2017]

Colorectal Cancer [2017]

  • $ 8658
  • Industry report
  • September 2017

Will new targeted therapies transform the treatment of colorectal cancer?Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. ...

  • Industries : Therapy, Cancer, Pathology
  • Countries : United States, United Kingdom
Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2017

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2017

  • $ 5637
  • Industry report
  • August 2017

Eliminating prescription barriers could break the tie at the top of the marketThe two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share, but one of them benefits ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact: Multiple Sclerosis (EU5) 2017

Market Access Impact: Multiple Sclerosis (EU5) 2017

  • $ 5637
  • Industry report
  • July 2017

Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5 In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market ...

  • Industries : Health Services
  • Countries : France, Germany, Italy, Spain, United Kingdom
Market Access Impact: Haemophilia B (EU5)

Market Access Impact: Haemophilia B (EU5)

  • $ 5637
  • Industry report
  • July 2017

Leading brands have room to growAt least 30% of the haematologists we surveyed don’t prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there’s ...

  • Industries : Health Services
  • Countries : Sweden
Medical Affairs Reputations: Melanoma (EU5) 2017

Medical Affairs Reputations: Melanoma (EU5) 2017

  • $ 6755
  • Industry report
  • July 2017

Find out what the leading team gets right, and what the trailing team gets wrongThe medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists ...

  • Industries : Health Services
  • Countries : United Kingdom
Market Access Impact (EU5) [Melanoma]

Market Access Impact (EU5) [Melanoma]

  • $ 5637
  • Industry report
  • February 2017

DescriptionTwo brands are neck and neck for 2nd place. Would eliminating barriers break the tie?In the EU5, market barriers affect nearly a quarter of all melanoma prescriptions, giving the top brand a ...

  • Industries : Health Services
  • Countries : United States, United Kingdom



Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on